What a talar dome lesion actually is

You've had an ankle sprain — or several — and the pain simply hasn't gone away. Deep in the joint, activity still triggers an ache; some days there's a click, some days a subtle swelling. If that sounds familiar, a talar osteochondral lesion (OLT) is a common explanation.

The talus is the bone that forms the floor of the ankle joint. Its domed upper surface is coated in articular cartilage — the smooth, load-bearing tissue that allows the joint to move without friction. An OLT is damage to that cartilage layer, sometimes reaching into the underlying bone. The injury is far from rare: roughly 50–70% of acute ankle sprains involve some degree of cartilage or bone bruising at the talar dome, and repeated instability can drive the process further.

OLTs exist on a spectrum. At one end sits a superficial crack in the cartilage with the bone beneath intact; at the other, a partially detached fragment sitting loose in the joint. That distinction matters enormously for what happens next — and it cannot be resolved on a standard X-ray alone.

Why X-rays often miss the damage

A normal ankle X-ray is genuinely reassuring for one thing: it confirms there is no fracture and no gross bony displacement. What it cannot do is show cartilage. Because X-ray works by detecting density differences in hard tissue, the articular surface is essentially invisible — which is why plain radiographs miss up to half of all talar dome lesions, including clinically significant ones.

MRI closes that gap. A single scan images the cartilage surface directly, identifies oedema and haemorrhage in the subchondral bone beneath it, picks up non-displaced fragments that are still in position, and assesses the surrounding ligaments and tendons for co-existing injury. That combination of information in one examination is why MRI is the recommended next step when ankle pain persists — not another X-ray series.

CT does appear later in the pathway, but not as a diagnostic tool for cartilage injuries. Its role is preoperative planning: mapping the precise dimensions of a lesion, evaluating the depth and architecture of the underlying bone, and helping a surgeon determine how the joint can be accessed. At the diagnostic stage, CT adds little because it shares the same fundamental limitation as plain radiographs — it cannot visualise cartilaginous tissue.

The practical prompt: if ankle pain has not settled within six to eight weeks of a sprain and X-ray appears normal, MRI is the appropriate next investigation.

What your MRI is actually showing

Four variables shape how a specialist reads an ankle MRI report.

Cartilage surface integrity — whether the articular surface is smooth and intact, showing a fissure, or has a full-thickness breach reaching the bone below.

Subchondral bone changes — oedema (bone bruising) and cyst formation in the bone directly underneath the cartilage indicate how far the process has penetrated, and whether the bone is likely to remodel or requires structural support.

Fragment status — whether any detached piece of cartilage or bone remains stable in its bed, or has shifted and become loose in the joint.

Lesion size — the single most important predictor of outcome across all treatment approaches. Chuckpaiwong and colleagues found no treatment failures for lesions below approximately 15 mm in average diameter, while a separate analysis by Choi et al. (2009) placed the cut-off for successful arthroscopic treatment at an MRI-measured area of less than 150 mm². Larger lesions, cystic lesions, and displaced fragments carry a materially lower probability of settling without surgery — and a stronger case for prompt specialist review rather than a prolonged wait.

The specialist combines all four variables with symptom severity, ankle stability, and the functional demands placed on the joint. Imaging provides the map; the clinical picture determines which route is appropriate.

The conservative treatment pathway and what to expect

For stable, non-displaced lesions — where the cartilage surface is intact and no fragment has shifted — non-operative management is the correct starting point, not a preliminary step before 'real' treatment.

The 95% resolution figure that sometimes appears in patient literature applies specifically to skeletally immature patients: adolescents with open growth plates whose subchondral bone retains strong remodelling capacity. In skeletally mature adults, the natural history is less reliably favourable, though a structured non-operative trial of three to six months remains standard for smaller lesions before surgical review is considered.

Phase 1 — protect and unload

The acute and subacute phase centres on reducing mechanical load on the damaged area. This typically means a period of protected weight bearing in a removable boot, or occasionally a short spell in a cast, to allow bone oedema to settle and any early reparative response to begin undisturbed. Activity modification during this phase is not optional: continuing to load an irritated talar dome tends to perpetuate symptoms rather than resolve them.

Phase 2 — structured rehabilitation

Once pain permits, the focus shifts to a physiotherapy programme specifically targeting ankle proprioception, neuromuscular control, and lower-limb strength. General ankle exercises are insufficient; the goal is restoring the joint's ability to stabilise dynamically under load, which both supports recovery and reduces the risk of re-injury.

Injection adjuncts

When pain persists despite rehabilitation, intra-articular injections may be considered as adjuncts. Corticosteroid addresses acute inflammation and symptom control. Hyaluronic acid targets joint lubrication. Platelet-rich plasma (PRP) is used for its regenerative potential, supported by safety data but without definitive ankle-specific randomised trial evidence at present — a specialist assessment will clarify whether it is appropriate for a given presentation.

When conservative management stops being enough

Persistent symptoms beyond three to six months of structured conservative care — or pain and functional limitation that meaningfully restrict daily activity sooner — are the standard threshold for specialist review. At that point, the treatment options widen along a spectrum from minimally invasive to theatre-based procedures, with lesion size the primary determinant of which is appropriate.

For patients who prefer to defer formal surgery, or who are not yet clear surgical candidates, injectable collagen scaffold approaches such as the ChondroFiller injection — delivered as an ultrasound-guided outpatient procedure — represent an intermediate option that sits beyond standard injection therapy but stops short of operating-theatre intervention. Whether a given lesion size and cartilage status make this approach suitable requires specialist assessment.

For lesions below approximately 10 mm in diameter or 2 cm² in area, arthroscopic bone marrow stimulation (microfracture or drilling) is the established first-line operative option. A meaningful limitation is that marrow stimulation produces fibrocartilage rather than native hyaline cartilage — the repair tissue is mechanically less durable than the original surface — which is why outcomes tend to decline as lesion size increases beyond those thresholds.

Larger lesions, cystic defects, or cases where marrow stimulation has already been attempted without success are generally managed with osteochondral autograft transfer (OATS) or autologous chondrocyte implantation, both of which aim to restore a closer approximation of the original cartilage architecture.

Escalation decisions are always made by a specialist who has reviewed the full MRI alongside the clinical history, ankle stability, and the patient's functional demands — not from a single imaging variable in isolation.

Getting a specialist assessment in London

Reading an MRI report — even one that uses phrases such as "osteochondral defect" or "subchondral oedema" — does not, on its own, determine a treatment plan. The four variables covered in this article (cartilage surface integrity, subchondral bone changes, fragment status, and lesion size) are inputs to a clinical decision, not a verdict in themselves. A specialist's job is to map those findings against your symptoms, ankle stability, and functional demands to identify the most appropriate pathway — conservative, injectable, or operative.

If imaging has flagged a talar dome lesion and your ankle has not settled as expected despite appropriate management, specialist assessment is the logical next step. For patients exploring the injectable collagen scaffold route as a less invasive alternative, the London Cartilage Clinic on Harley Street offers assessment for the ChondroFiller injection pathway as part of a full clinical evaluation. Book at londoncartilage.com.

1. [1] Osteochondritis dissecans — Wikipedia. https://en.wikipedia.org/?curid=3762029 https://en.wikipedia.org/?curid=3762029